Pharmaceutical jobs provider Allergan has expressed confidence that its leading product Botox will help it to deliver strong growth over the coming years.
David Pyott, chief executive officer of the company, stated at the recent Reuters Health Summit that the firm has now made a full recovery from a two-year slump caused by the recession.
In the first quarter of 2011, it saw a ten per cent year-on-year sales increase for Botox, which is best known as an anti-wrinkle therapy but has a wide range of other indications.
For example, it was ratified by UK regulators as a treatment for chronic migraines last year, while it is also currently under consideration for approval as an overactive bladder therapy option.
In addition, Allergan is seeing strong sales for its prescription eye drugs, which represent its largest product line and main area of focus.
Mr Pyott said: "I've been on this job for 13 years and this is about the best it's ever been."